相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination
Smita Joshi et al.
VACCINE (2023)
HPV type-specific trends in cervical precancers in the United States, 2008 to 2016
Julia W. Gargano et al.
INTERNATIONAL JOURNAL OF CANCER (2023)
Design of a phase III efficacy, immunogenicity, and safety study of 9-valent human papillomavirus vaccine in prevention of oral persistent infection in men
Anna R. Giuliano et al.
CONTEMPORARY CLINICAL TRIALS (2022)
Rationale and design of a double-blind randomized non-inferiority clinical trial to evaluate one or two doses of vaccine against human papillomavirus including an epidemiologic survey to estimate vaccine efficacy: The Costa Rica ESCUDDO trial
Carolina Porras et al.
VACCINE (2022)
Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial
Stephen E. Goldstone et al.
LANCET INFECTIOUS DISEASES (2022)
Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer
J. M. Palefsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial
Deborah Watson-Jones et al.
Lancet Global Health (2022)
National Vaccination Coverage Among Adolescents Aged 13–17 Years — National Immunization Survey-Teen, United States, 2021
Cassandra Pingali et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)
Immunogenicity, safety, and efficacy of the HPV vaccines among people living with HIV: A systematic review and meta-analysis
Lisa Staadegaard et al.
ECLINICALMEDICINE (2022)
Sexually Transmitted Infections Treatment Guidelines, 2021
Kimberly A. Workowski et al.
MMWR Recommendations and Reports (2021)
Estimated Prevalence and Incidence of Disease-Associated Human Papillomavirus Types Among 15-to 59-Year-Olds in the United States
Rayleen M. Lewis et al.
SEXUALLY TRANSMITTED DISEASES (2021)
Long-term effectiveness of the nine-valent human papillomavirus vaccine in Scandinavian women: interim analysis after 8 years of follow-up
Susanne K. Kjaer et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2021)
Significant Declines in Juvenile-onset Recurrent Respiratory Papillomatosis Following Human Papillomavirus (HPV) Vaccine Introduction in the United States
Elissa Meites et al.
CLINICAL INFECTIOUS DISEASES (2021)
The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study
Milena Falcaro et al.
LANCET (2021)
Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study
Partha Basu et al.
LANCET ONCOLOGY (2021)
High Prevalence of Anal High-Grade Squamous Intraepithelial Lesions, and Prevention Through Human Papillomavirus Vaccination, in Young Men Who Have Sex With Men Living With Human Immunodeficiency Virus
Joel M. Palefsky et al.
CLINICAL INFECTIOUS DISEASES (2021)
Real-World Effectiveness of Human Papillomavirus Vaccination Against Cervical Cancer
Susanne K. Kjaer et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
Declines in Prevalence of Human Papillomavirus Vaccine-Type Infection Among Females after Introduction of Vaccine - United States, 2003-2018
Hannah G. Rosenblum et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)
Effect of Training Pediatric Clinicians in Human Papillomavirus Communication Strategies on Human Papillomavirus Vaccination Rates A Cluster Randomized Clinical Trial
Peter G. Szilagyi et al.
JAMA PEDIATRICS (2021)
Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial
Aimee R. Kreimer et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis
Catherine de Martel et al.
LANCET GLOBAL HEALTH (2020)
Effects of the COVID-19 Pandemic on Routine Pediatric Vaccine Ordering and Administration - United States, 2020
Jeanne M. Santoli et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2020)
Adjuvant Human Papillomavirus Vaccine to Reduce Recurrent Cervical Dysplasia in Unvaccinated Women A Systematic Review and Meta-analysis
Katie Lichter et al.
OBSTETRICS AND GYNECOLOGY (2020)
HPV Vaccination and the Risk of Invasive Cervical Cancer
Jiayao Lei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries
Susanne K. Kjaer et al.
ECLINICALMEDICINE (2020)
Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis
Melanie Drolet et al.
LANCET (2019)
Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices
Elissa Meites et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2019)
Near Real-Time Surveillance to Assess the Safety of the 9-Valent Human Papillomavirus Vaccine
James G. Donahue et al.
PEDIATRICS (2019)
Ten Years of Human Papillomavirus Vaccination in the United States
Lauri E. Markowitz et al.
ACADEMIC PEDIATRICS (2018)
Declines in Anogenital Warts Among Age Groups Most Likely to Be Impacted by Human Papillomavirus Vaccination, United States, 2006-2014
Elaine W. Flagg et al.
AMERICAN JOURNAL OF PUBLIC HEALTH (2018)
Explanations for the high potency of HPV prophylactic vaccines
John Schiller et al.
VACCINE (2018)
Screening for Cervical Cancer US Preventive Services Task Force Recommendation Statement
Susan J. Curry et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Trends in Human Papillomavirus–Associated Cancers — United States, 1999–2015
Elizabeth A. Van Dyne et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2018)
Safety of Human Papillomavirus Vaccines: An Updated Review
Anastasia Phillips et al.
DRUG SAFETY (2018)
Worldwide burden of cancer attributable to HPV by site, country and HPV type
Catherine de Martel et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Prevalence of Human Papillomavirus Among Females After Vaccine Introduction-National Health and Nutrition Examination Survey, United States, 2003-2014
Sara E. Oliver et al.
JOURNAL OF INFECTIOUS DISEASES (2017)
Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials
Joseph E. Tota et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials
Joseph E. Tota et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women
Ole-Erik Iversen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States
Julianne Gee et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2016)
Interventions to increase HPV vaccination coverage: A systematic review
Elizabeth A. Smulian et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2016)
Carcinogenic human papillomavirus infection
Mark Schiffman et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes
David Mesher et al.
EMERGING INFECTIOUS DISEASES (2016)
US Assessment of HPV Types in Cancers: Implications for Current and 9-Valent HPV Vaccines
Mona Saraiya et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women
E. A. Joura et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Immunogenicity and safety of the 9-valent HPV vaccine in men
X. Castellsague et al.
VACCINE (2015)
US Assessment of HPV Types in Cancers: Implications for Current and 9-Valent HPV Vaccines
Mona Saraiya et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Reduction in Human Papillomavirus (HPV) Prevalence Among Young Women Following HPV Vaccine Introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010
Lauri E. Markowitz et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
Global Burden of Human Papillomavirus and Related Diseases
David Forman et al.
VACCINE (2012)
A Review of Clinical Trials of Human Papillomavirus Prophylactic Vaccines
John T. Schiller et al.
VACCINE (2012)
End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age
X. Castellsague et al.
BRITISH JOURNAL OF CANCER (2011)
Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males
Anna R. Giuliano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
HPV Vaccine against Anal HPV Infection and Anal Intraepithelial Neoplasia
Joel M. Palefsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women
J. Paovonen et al.
LANCET (2009)
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
Suzanne M. Garland et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up
L. L. Villa et al.
BRITISH JOURNAL OF CANCER (2006)
Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women
Stan L. Block et al.
PEDIATRICS (2006)
分享论文
